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Abstract: Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and deadly
type of primary malignant brain tumor, with a patient’s median survival rate ranging from 15 to
17 months. The current treatment for GBM involves tumor resection surgery based on MRI image
analysis, followed by radiotherapy and treatment with temozolomide. However, the gradual
development of tumor resistance to temozolomide is frequent in GBM patients leading to subsequent
tumor regrowth/relapse. For this reason, the development of more effective therapeutic approaches
for GBM is of critical importance. Low tumor oxygenation, also known as hypoxia, constitutes a
major concern for GBM patients, since it promotes cancer cell spreading (invasion) into the healthy
brain tissue in order to evade this adverse microenvironment. Tumor invasion not only constitutes a
major obstacle to surgery, radiotherapy, and chemotherapy, but it is also the main cause of death in
GBM patients. Understanding how hypoxia triggers the GBM cells to become invasive is paramount
to developing novel and more effective therapies against this devastating disease. In this review,
we will present a comprehensive examination of the available literature focused on investigating how
GBM hypoxia triggers an invasive cancer cell phenotype and the role of these invasive proteins in
GBM progression.
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1. Introduction
Glioblastoma multiforme (GBM) is the most common type of primary malignant brain tumor,
classified by the World Health Organization (WHO) as a grade IV astrocytoma. Patients’ median
survival is low, ranging from 15 to 17 months [1–3]. Under the Stupp protocol, the current treatment for
GBM commences with tumor resection surgery based on MRI image analysis (if possible depending
on the location and size of the tumor), followed by radiotherapy and treatment with temozolomide [4].
Radiotherapy alone can significantly increase median survival, although the most common radiological
response is to stabilize the disease but ultimately tumor progression follows. Subgroup analysis of
GBM patients demonstrated that a discernible clinical response to temozolomide was principally
limited to those tumors containing a specific epigenetic alteration, namely promoter methylation of
the O6-methylguanine DNA methyltransferase (MGMT) gene [5]. Critically, while these patients show
an improvement (compared to surgical resection and radiotherapy alone), almost all demonstrate
eventual progressive disease in the absence of MGMT promoter methylation [6]. The development of
novel and more effective therapeutic approaches for GBM is paramount, taking into account the low
median survival rate for GBM patients even when undergoing the current treatment protocols.
Genomic studies have identified four subtypes of GBM based on gene expression patterns, namely
the classical, proneural, neural, and mesenchymal subtypes [7,8]. The classical subtype was shown to
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present amplification or mutation of the epidermal growth factor receptor (EGFR) and high expression
of the neural precursor and stem cell marker NES, as well as of the Notch (NOTCH3, JAG1, and LFNG)
and Sonic hedgehog (SMO, GAS1, and GLI2) signaling pathway proteins [8]. The proneural subtype
shows amplification of platelet-derived growth factor receptor A (PDGFRA) and deletion of the
TP53 tumor suppressor gene [8]. The proneural signature further contains high expression of several
proneural developmental genes, such as SOX, DCX, DLL3, ASCL1, and TCF4 [9]. Interestingly, within
this subtype isocitrate dehydrogenase (IDH) gene mutations associated with improved patient outcome
are also observed [8]. The neural subtype is characterized by the expression of neuron markers such
as NEFL, GABRA1, SYT1, and SLC12A5 [8]. Finally, the mesenchymal subtype as the name indicates
expresses mesenchymal markers such as CHI3L1 and MET [9] and has been associated with mutations
or deletion of the neurofibromin 1 (NF1) gene [8,10,11]. Neurofibromin protein stimulates RAS intrinsic
GTPase activity, thereby promoting the conversion of active RAS-GTP into its inactive RAS-GDP state.
Hence, the loss of NF1 gene results in sustained intracellular levels of active RAS-GTP, subsequently
promoting oncogenesis [12].
More recently, the WHO updated the classification of the tumors of the Central Nervous System (CNS)
using molecular parameters in addition to histology [13]. According to the new WHO classification,
CNS tumor diagnoses should consist of the histopathological name followed by the genetic features.
This new classification subdivides GBM into GBM, IDH-wildtype (approximately 90% of all cases) and
GBM, IDH-mutant. The IDH enzymes are responsible for the oxidative carboxylation of isocitrate to
α-ketoglutarate producing nicotinamide adenine dinucleotide phosphate (NADPH). Mutations in the
IDH genes lead to an approximately 50% decrease of the normal IDH activity. Taking into account the
impaired function of the mitochondria in GBM cells, the production of bioenergy and intermediates is
decreased in IDH mutant GBM, hence the tumor growth is impaired when compared to IDH-wildtype
GBM, which translates into a better overall patient prognosis [14].
The majority of GBMs develop de novo and as such are classified as primary GBMs. These tumors
tend to grow rapidly and usually do not have IDH mutations. However, a minority of GBMs can
slowly develop from low-grade astrocytomas, known as secondary GBMs. Mutations in IDH are more
frequently observed in this class of GBMs [15]. Histologically, both primary and secondary GBMs
are identical. GBM distinctive pathological features include necrotic foci with surrounding cellular
pseudopalisades and microvascular hyperplasia (Figure 1), which are believed to play a main role in
the accelerated growth and invasion of GBM [16]. Research on the origin of pseudopalisades suggests
that this morphological structure is created by tumor cells migrating away from a central hypoxic
(poorly oxygenated) region and forming an invasive front [17,18]. Microvascular hyperplasia is an
exacerbated form of angiogenesis that occurs in response to the secretion of proangiogenic factors
(i.e., vascular endothelial growth factors (VEGFs), interleukin-8 (IL-8)) by the cells that form the
pseudopalisades [19]. Microvascular hyperplasia is characterized by a large number of enlarged and
rapidly dividing endothelial cells, pericytes, and smooth muscle cells that form tuft micro-aggregates
at the leading edge of sprouting blood vessels [20]. It can take the shape of ‘glomeruloid bodies’ that
constitute a characteristic feature of GBM. The excessive VEGF production observed in GBM favors
the hyper-proliferation and recruitment of endothelial cells in detriment to pericytes that provide
coverage and support to the blood vessels [21]. This results in the formation of defective and permeable
blood vessels that can easily collapse yielding hypoxic foci within the GBM. Low tumor oxygenation,
also known as hypoxia, constitutes a major problem for GBM patients, since it promotes tumor cell
spreading (invasion) into the healthy brain tissue in order to evade this adverse environment [22,23].
Tumor invasion not only constitutes a major obstacle to therapy, but it is also the main cause of
death in GBM patients. For this reason, an increasing amount of research has been focused on
characterizing the molecular and cellular mechanisms that regulate GBM cell invasiveness. Since the
hypoxic environment is a major inducer of the GBM cell invasive phenotype, understanding how
hypoxia triggers the GBM cells to invade is paramount for the development of novel and more
effective therapies against this devastating disease. In this review, we will present a comprehensive
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examination of the available literature regarding how GBM hypoxia triggers an invasive cancer cell
phenotype, the role of these invasive proteins in GBM progression, and whether any of these are
therapeutically targetable.
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Hypoxia is frequent in solid tumors, being the natural consequence of the increased oxygen diffusion 
distance due to tumor expansion. The clinical-pathological effects of hypoxia in GBM can be observed 
by magnetic resonance imaging (MRI) where significant oxygen diffusion restriction is detected, 
consistent with absent or defective blood flow [20,24,25]. Molecular markers of hypoxia, such as 
hypoxia inducible factor 1 (HIF-1) and VEGF staining, as well as tumor vascularity, can be detected 
on dynamic contrast enhanced MRI and correlate with worse progression-free and overall patient 
survival [24,26]. Microscopy analyses of GBMs reveal multiple hypoxic regions and a widespread 
invasion in the growing periphery of these tumors [23]. Hypoxia occurs in GBM due to increased cell 
proliferation/tumor growth linked to an erratic tumor neovascularization that leads to poor oxygen 
Figure 1. GBM distinctive pathological features. B is characterized by necrotic foci with
surrounding cellular pseudopalisades and microvascular hyperplasia. Pseudopalisades are created
by tumor cells migrating away from a central hypoxic (low oxygenated) region and forming an
invasive front. Microvascular hyperplasia is an exacerbated form of angiogenesis that occurs in
response to the secretion of proangiogenic factors (e.g., vascular endothelial growth factors (VEGFs),
interleukin-8 (IL-8)) by the cells that form the pseudopalisades.
2. Hypoxia in GBM
Hypoxia is a condition in which an organism or a cell is deprived of adequate oxygenation
(e.g., when oxygen demand exceeds oxygen supply, O2 partial pressure (pO2) less than 10 mmHg).
Hypoxia is frequent in solid tumors, being the natural consequence of the increased oxygen diffusion
distance due to tumor expansion. The clinical-pathological effects of hypoxia in GBM can be observed
by magnetic resonance imaging (MRI) where significant oxygen diffusion restriction is detected,
consistent with absent or defective blood flow [20,24,25]. Molecular markers of hypoxia, such as
hypoxia inducible factor 1 (HIF-1) and VEGF staining, as well as tumor vascularity, can be detected
on dynamic contrast enhanced MRI and correlat with worse progression-free overall patient
survival [24,26]. Microscopy anal ses of GBMs eveal multiple hypoxic regions and a wid spread
invasion in the growing periphery of these tumors [23]. Hypoxia occurs in GBM due t increased
cell proliferation/tumor growth linked to an erratic tumor neovascularization that leads to poor
oxygen diffusion [27]. GBM vessels are tortuous, disorganized, highly permeable, and characterized by
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abnormalities in their endothelial walls due to the lack of pericyte coverage [28–30]. These vessels also
have significantly larger diameters and thicker basement membranes compared to those of the normal
brain [31]. At the tumor tissue level, the occurrence of microvascular thromboses that lead to vessel
occlusion is commonly observed, further promoting intratumoral hypoxia [25]. Intratumoral blood
flow is thus impeded, creating a heterogeneous tumor environment with respect to oxygenation
and interstitial fluid pressure [32]. Inconsistent intratumoral oxygenation leads to hypoxia, acidosis,
and necrosis, whereas the increased hydrostatic pressure outside of the GBM vasculature promotes
intratumoral edema, a major cause of morbidity for GBM patients [33].
3. HIF Transcription Factors
HIF transcription factors constitute the master regulators of the hypoxia adaptive response. HIFs are
heterodimeric complexes constituted by O2-regulated α subunits (HIF-1α, EPAS1/HIF-2α, or HIF-3α)
and a constitutively expressed β subunit, HIF-1β, also known as an aryl hydrocarbon receptor nuclear
translocator (ARNT) [34,35]. Of the three α subunits, HIF-1α and HIF-2α are the best studied and
considered to be the main regulators of the hypoxia response. HIF-1α is ubiquitously expressed,
whereas HIF-2α is selectively expressed in distinct cell populations [34]. HIF-1α and HIF-2α have both
overlapping and distinct target genes [35] and are differentially regulated under various physiological
and pathological conditions [36]. For instance, they play different roles in tumorigenesis depending
on specific tumor microenvironments [34,35]. The existence of multiple variants of HIF-3α has made
it very challenging to elucidate HIF-3 functions. Distinct HIF-3α variants are expressed in different
tissues and are differentially regulated by hypoxia. While the full-length HIF-3α protein has been
shown to function as a transcription activator, triggering a unique transcriptional program in response
to hypoxia [37], some HIF-3α variants act as dominant-negative regulators of HIF-1/2α functions [38].
The protein structures of HIF-1α, HIF-2α, and HIF-1β subunits contain a basic helix-loop-helix (bHLH),
a Per-Arnt-Sim (PAS) domain, and a C-terminal (C-TAD) domain, while HIF-α subunits contain
an additional oxygen-dependent degradation domain (ODD) and an N-terminal domain (N-TAD).
The bHLH and PAS domains are involved in heterodimer formation and binding to hypoxia responsive
elements (HRE) within the promoters of HIF target genes, whereas the N-TAD and C-TAD domains are
involved in transactivation through interactions with the transcriptional coactivators p300/CBP [39–41].
HIF-3α can exist in many different variants, with distinct deletions of the domains described above
(for a detailed description, see [38]). Under normoxic conditions (normal oxygen levels), two prolyl
residues within the HIF-α subunits are hydroxylated by prolyl hydroxylases 1-3 (PHD1-3). This allows
the binding of the von Hippel-Lindau (VHL) protein to the HIF-α subunit. The VHL protein then recruits
E3 ubiquitin ligases, which target HIF-α for proteasomal degradation [42–44]. PHDs are 2-oxoglutarate-
and iron-dependent dioxygenases, whose activities are positively regulated by O2. Hence, hypoxia leads
to PHDs inhibition and subsequent stabilization of the HIF-α subunits. HIF-α then translocates to the
nucleus and binds to the HIF-1β subunit and cofactors such as p300/CBP; this complex subsequently
binds to HRE within promoters of target genes and orchestrates a concerted transcriptional response to
hypoxia [45–47]. Factor-inhibiting HIF (FIH) is also an O2 regulated hydroxylase that blocks the interaction
between HIF-α and the transcriptional activators, p300/CBP, through asparagine hydroxylation of HIFα,
attenuating HIF transactivation activity [48,49].
Genetic alterations that lead to HIF activation have been reported in GBM, further exacerbating
the hypoxia response in this type of tumor. The activation of the epidermal growth factor receptor
(EGFR) and the loss of tumor suppressor function (p53, PTEN) are common in GBM and can affect HIF
expression. EGFR gene mutation and/or amplification is frequent in GBM [50]. The most common
EGFR gene mutation (EGFRvIII) consists of the deletion of exons 2–7, resulting in a constitutively
active and ligand independent receptor [51]. Initiation of EGFR signaling by ligand binding (which is
exacerbated in GBM cells over-expressing EGFR) or gene mutation (i.e., EGFRvIII) results in activation
of the PI3K/AKT/mTOR pathway with the subsequent up-regulation of HIF-1α (Figure 2A) [52,53].
GBM has a 20% to 40% incidence of phosphatase and tensin homolog (PTEN) deletions [54]. PTEN is
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the main inhibitor of the PI3K/AKT signaling pathway. Consequently, the loss of PTEN leads to
increased HIF-1α via the PI3K/AKT/mTOR pathway (summarized in Figure 2A). It has been proposed
that p53 protein may lead to the inhibition of HIF activity in hypoxia by promoting MDM2-mediated
ubiquitination and the degradation of HIF-1α [55]. Therefore, the loss of the p53 gene, which is
common in GBM, will lead to HIF-1α stabilization (Figure 2B). Other proteins that have been shown
to regulate HIF-1α expression under hypoxic conditions leading to increased GBM cell migration
and invasion include FAT atypical cadherin 1, integrins αvβ3 and αvβ5, Hypoxia-inducible protein
2 (HIG2), and geranylgeranyltransferase I (GGTI) [56–59].
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Figure 2. Gen tic alterations that lead to HIF activatio i . ( ) F gene amplification and/or
overexpression is frequent in GBM. The most com on EGFR gen muta ion (EGFRvII ) consi t in the
deletion of exons 2–7, resulting in a constitutively active and ligand indepe e t receptor. Initiati n of
EGFR/EGFRvIII signaling by ligand binding, gene amplification, or mutation esul s in activa io of
the PI3K/AKT/mTOR pathway with t e subsequent up-regula ion of HIF-1α. PTEN gene deletion is
common in GBM. PTEN protein is the main inhibitor of the PI3K/AKT signalin pathway, as such
loss of PTEN function leads to increased HIF-1α via the PI3K/AKT mTOR pathway; (B) It has been
proposed that p53 may lead to inhibition of HIF activity in hypoxia by promoting MDM2-mediated
ubiquitination and degradation of HIF-1α. Therefore, the loss of the p53 gene, which is common in
GBM, will lead to HIF-1α stabilization.
As a result of our understanding of the deregulation of the PI3K/AKT/mTOR signaling pathway
in GBM, its targeting has attracted significant attention for the development of anti-cancer therapeutics.
Initially, rapamycin analogs (mTOR inhibitors) were tested, although these demonstrated little impact
on overall patient survival [60,61]. BKM120 (Novartis) is a pan-class I PI3K inhibitor without mTOR or
Vps34 activity that can cross the blood brain barrier (BBB), which is critical for clinical applications
against GBM. Pr clinical studies d monstrated that th survival of NOD/SCID mice harboring
intracerebral U87MG tumor xenografts significa tly improved fo lowing BKM120 treatment [62].
To da e, there is an ongoing phase II linical trial with this agent in patients with first or second GBM
recurrence (clinical trial #NCT01339052) that is being coordinated by the Dana-Farber/Brigham nd
Women’s Cancer Cent r, U.S.A. Beyond single agent inhibitors, the dual inhibition of both th PI3K
and mTOR pathway is considered a more effective therapeutic strategy, the most extensively studied
being BEZ235 (Novartis), a dual PI3K/mTORC1/2 inhibitor [63]. BEZ235 has been used in a wide
range of in vitro studies [64] and tested against glioma cells where BEZ235 treatment induced G1
cell-cycle arrest and autophagy, and reduced VEGF expression [65]. Furthermore, BEZ235 significantly
increased the survival of tumor bearing mice [66]. Recent studies have highlighted conflicting results
regarding the effectiveness of this agent in vivo where BEZ235 demonstrated antitumor efficacy with
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improved survival against U87MG orthotopic gliomas in one study [67]. However, very little to no
efficacy was observed in another independent orthotopic xenograft model study [68]. It is important
to note that many PI3K/mTOR inhibitors demonstrate weak affinities for ABC transporters, but in
spite of this, can still achieve target inhibition in GBM albeit with modest single-agent efficacy. For this
reason, it is likely that these drugs will require combination-treatments with other (BBB penetrable)
inhibitors and agents.
HIF-induced transcription regulates hundreds of genes that promote angiogenesis, erythropoiesis,
migration, cell survival, proliferation, epithelial to mesenchymal transition (EMT), the recruitment of
inflammatory cells, invasion, metastasis and metabolic reprogramming, and of particular importance,
the shifting of cellular metabolism from oxidative phosphorylation to glycolysis [36,45,69–71].
However, the alterations of specific genes and their clinical significance in GBM remain to be better
explored. Hypoxia is a main promoter of GBM invasion which is tightly linked with poor patients’
survival and chemoresistance. For this reason, identifying and characterizing hypoxia induced proteins
that regulate GBM invasion is key for the development of novel and more effective therapies against
this deadly type of tumor.
4. Hypoxia Driven Up-Regulation of Invasion Proteins in GBM
In this review, we will perform a thorough examination of the literature focused in identifying
hypoxia responsive invasion genes and proteins and characterizing the molecular mechanisms by
which these proteins contribute to GBM progression.
4.1. Extracellular Matrix Degradation and Remodeling
Degradation and remodeling of the extracellular matrix (ECM) that surrounds the tumor are
essential processes for cancer cell invasion, creating spaces and scaffolding that allow tumor cell
proliferation/growth and migration (spreading) away from the initial tumor site [72].
Carbonic anhydrase (CA) IX has been shown to be over-expressed in GBM [73–75] and CAIX gene
expression has been shown to be regulated by hypoxia [76]. High expression of CAIX was identified as
an independent prognostic factor for poor survival in patients with GBM [77]. An in vitro study using
an siRNA approach to knockdown CAIX expression in the GBM cell lines, U251 and Ln 18, showed
that CAIX was not only important for GBM cell attachment and invasion, but also for providing radio-
and chemo-resistance [77]. CAIX is a membrane bound, zinc dependent enzyme that catalyzes CO2
hydration into bicarbonate with a proton release [78]. Since CO2 is a main by-product of oxidation,
CAs play a main role in maintaining acid/base homeostasis in cells. CAIX has the highest catalytic
activity among all membrane bound CAs due to the presence of a unique proteoglycan fragment
located close to its active site [79,80]. The CAIX active site is located at the outer side of the plasma
membrane, so protons are generated on the extracellular space. The extrusion of hydrogen ions into
the extracellular space by CAIX thus contributes to the regulation of the intracellular pH, and at the
same time, to the acidification of the extracellular space surrounding the GBM, thus leading to ECM
and surrounding tissue degradation and creating an environment conductive to enhanced invasion.
Acetazolamide (a CAIX inhibitor) has been shown to effectively treat 2D or 3D GBM models [81].
These results indicate that CAIX constitutes a promising therapeutic target for GBM. Furthermore, the
effectiveness of this agent was significantly enhanced when acetazolamide was incorporated into a
polymeric poly(ethylene glycol)-block-poly(lactide-co-glycolide) nano-carrier (that readily crosses the
BBB) and used to treat 3D spheroid models [81]. A second CAIX inhibitor, Indisulam, is currently in
Phase II of clinical trials for the treatment of a range of cancers, including metastatic melanoma, lung,
and metastatic breast cancer where brain metastasis is frequently observed [82].
Epidermal growth factor receptor (EGFR) is amplified in approximately 50% of all GBMs.
Expression of the mutant variant of EGFR that lacks exons 2–7 (EGFRvIII), leading to the constitutive
activation of this receptor, is particularly common and has been shown to be tightly linked with poor
patients’ prognosis [83]. A recent study using U87MG and LN229 GBM cell lines over-expressing
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EGFRvIII showed that hypoxia stimulates the interaction of EGFRvIII with the integrin β3 in GBM
cells, leading to EGFRvIII protein stabilization. Tumor cells adhere to the ECM via integrin receptors
which induce the activation of focal adhesion signaling and the subsequent degradation of the ECM,
creating a path for cancer cell invasion of adjacent tissues [84]. Interaction of integrin β3 with EGFRvIII
stimulated the activation of an integrin β3/SRC/FAK/EGFRvIII signaling axis that led to the activation
of ERK1/2 (MAPK), AKT, and STAT3 signaling pathways in the GBM cells and the up-regulation of
the cancer cell invasion markers, matrix metalloproteinase-2 (MMP-2) and MMP-9, as well as integrin
β3, subsequently promoting GBM cell invasion [85].
EGFR is an extremely compelling therapeutic target for GBM treatment. In particular, mutant
EGFRvIII [86–88], which is reported in approximately 25–33% of all GBM cases [89]. The exclusive
expression of EGFRvIII can be targeted by multiple approaches including CAR T-cell therapy,
therapeutic vaccines, specific antibodies, or bi-specific T-cell engager approaches, (all extensively
reviewed in [90,91]). While there are clinical trials proposed for these agents, there are still significant
difficulties waiting to be solved in order to achieve the clinical translation of these agents into GBM
patients. These include off-tumor toxicity, potential cross reactivity complications, and a limited tumor
penetration capacity. However, the combination of targeting EGFRvIII and other treatment modalities
is considered to have significant potential to improve GBM patient prognosis.
Integrins αvβ3 and αvβ5 have also been shown to be recruited to the cell membrane of GBM
cells (e.g., U87MG and SF763) in response to hypoxia, leading to the activation of the focal adhesion
kinase (FAK) protein to promote tumor invasion [58]. This study also showed that the inhibition of
integrins αvβ3 or αvβ5, either by using a specific inhibitor or by siRNA, led to the decrease of HIF-1α
intracellular levels. The integrin-dependent HIF-1α regulation was mediated by FAK/RhoB dependent
inhibition of GSK3-β which promotes HIF-1α degradation in a VHL-independent manner [92].
The proteins of the integrin family constitute promising therapeutic targets. Cilengitide, the
most advanced specific integrin inhibitor, has demonstrated anti-tumor activity in both phase I and
phase II clinical trials for recurrent GBM [93–95]. Treatment of newly diagnosed GBM patients
with Cilengitide in combination with conventional therapy (radio-therapy and temozolomide) has
been encouraging [96], suggesting synergy of this drug with concomitant chemo- and radiation
therapy. A pivotal phase III study (CENTRIC) in newly diagnosed GBM patients was conducted [97].
Within this large phase III study, 3471 GBM patients were screened and 3060 had their MGMT
status tested. 926 tumours exhibited a methylated MGMT promoter, and from this cohort, 545 were
randomly assigned to the cilengitide (N = 272) or control (N = 273) groups. Patient median overall
survival was 26.3 months in the cilengitide treatment group and 26.3 months in the control group [97].
Unfortunately, none of the predefined clinical subgroups showed a benefit from cilengitide treatment
although the clinical trial did report that there was no overall additional toxic effects with cilengitide
treatment [97]. The addition of cilengitide to radiotherapy and temozolomide chemotherapy did
not improve patient outcome and the authors state that they will no further develop cilengitide as
an anti-GBM drug. Alongside the CENTRIC study, a second independent CORE clinical trial has
been conducted (clinical trials identifier NCT00813943). CORE is a Phase II clinical trial for newly
diagnosed GBM that recruited 265 GBM patients with the unmethylated MGMT gene promoter and
incorporated a two-times weekly or an intense, five-times weekly 2000 milligram cilengitide regimen
in combination with conventional treatment (temozolomide with concomitant radiation therapy,
followed by temozolomide maintenance therapy) for comparison to conventional treatment alone.
Temozolomide and radiotherapy treatment alone (N = 89) resulted in an overall survival (OS) time
of 13.4 months. In comparison, two-time weekly cilengitide treatment (N = 88) revealed an OS of
16.3 months. In contrast, intense cilengitide treatment (N = 88, at the same 2000 milligram dose)
had an overall survival of 14.5 months. When the cilengitide (two-times weekly, in combination
with temozolomide and radiotherapy) treatment was compared to temozolomide and radiotherapy
alone, and log rank calculated, a p value of 0.0328 was reported, indicating that bi-weekly cilengitide
alongside conventional treatment significantly improved overall patient survival. It is important to
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note, that while this CORE study has been completed and data is available (https://clinicaltrials.gov/
ct2/show/NCT00813943), this data has not yet been published. Despite the CENTRIC study set back,
promising data from the CORE study suggest that the integrins remain potential treatment targets
for GBM.
Procollagenlysine 2-oxoglutarate 5-dioxygenase 2 (PLOD2) is an enzyme that catalyzes collagen
cross-linking. A meta-analysis of seven independent GBM datasets, consisting of 861 GBM samples,
revealed that PLOD2 was significantly overexpressed across all GBM datasets analyzed compared to
a normal brain [98]. Analysis of PLOD2 mRNA expression from the Repository of Molecular Brain
Neoplasia Data (REMBRANDT) database (N = 178), further showed that PLOD2 mRNA expression
was significantly increased in GBM compared to lower grade gliomas and normal brain tissue [98].
Moreover, immunohistochemistry studies demonstrated increased PLOD2 expression associated with
increasing tumor grade. Staining for PLOD2 protein was absent or weak in non-neoplastic brain tissue
samples and grade II astrocytomas, increased in grade III astrocytomas and enhanced to an even greater
extent in GBM [98]. Analysis of The Cancer Research Atlas (TCGA) and the REMBRANDT databases
indicated that PLOD2 can constitute an effective diagnostic marker to distinguish lower grade gliomas
from GBM. Moreover, Kaplan-Meier plots based on the TCGA dataset showed significant lower
overall survival (OS) and progression free survival (PFS) in GBM patients with high PLOD2 expression
compared to patients with low PLOD2 [98]. In vitro studies using U87MG and U251 GBM cell lines
showed that hypoxia regulates PLOD2 protein expression in a HIF-1α dependent manner and that
the knockdown of PLOD2 by shRNA significantly inhibits GBM cell migration and invasion [98].
The molecular mechanism by which PLOD2 contributed to GBM cell migration and invasion involved
the phosphorylation of FAK (Tyr 397), leading to increased focal adhesion plaques under hypoxic
conditions [98]. Cancer cell invasion is closely related to its ability to stably adhere to the ECM [99]
and this process is regulated by a key protein, FAK [100,101]. In vivo studies using subcutaneous
and orthotopic xenograft mouse models further showed that PLOD2 promoted cross-linking of
collagen fibers around the tumors and enhanced ECM stiffness [98]. The formation of collagen
cross-links is initiated by PLOD2, which specifically hydroxylates lysine residues of the collagen
telopeptide area [102]. Enhanced ECM stiffness is commonly reported in many types of solid tumors,
including gliomas [103,104]. ECM stiffness increases principally as a result of collagen deposition and
crosslinking, and this has been shown to induce cancer cell invasion and metastasis [103–105].
There has been a concerted effort to target PLOD2, particularly in metastatic disease.
PLOD2 inhibition not only affects the cancer cells themselves, but it also impacts on the tumor
microenvironment, thus impairing metastasis. To date, several pharmacologic inhibitors have been
confirmed to have an anti-metastatic effect, while some compounds could be direct PLOD2 inhibitors
(reviewed in [106]). Minoxidil (a PLOD2 inhibitor) suppresses the expression of the PLOD2 protein,
and significantly reduces cancer cell migration, resulting in an anti-metastatic effect both in vitro
and in vivo [107,108]. Berberine can also suppress the expression of PLOD2 and has been shown to
inhibit pulmonary metastasis in melanoma [109]. Amentoflavone [110] and beta-carotene [111] also
decrease PLOD2 expression, reducing metastasis. Even though there have been substantial advances
in targeting PLOD2 in different types of cancer, to date, the effectiveness of these anti-PLOD2 agents in
GBM models remains unknown.
4.2. Epithelial to Mesenchymal Transition (EMT)
Increasing evidence supports that detachment of cancer cells from the initial tumor site is initiated
by the activation of an embryonic development program referred to as epithelial to mesenchymal
transition (EMT), whereby epithelial cells lose apicobasal polarity and cell–cell contact and acquire a
more motile and invasive mesenchymal phenotype [112].
CBF1 (also known as Recombination signal Binding Protein for immunoglobulin kappa J, RBPJ)
constitutes a key transcriptional regulator of the Notch signaling network. The Notch pathway
not only regulates stem cell maintenance, but is also a potent inducer of EMT in a variety of
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tumors [113]. A recent study showed that down regulation of CBF1 expression by shRNA in GBM
cells (e.g., GBM1, 407p, JHH) leads to the efficient suppression of EMT activators, including zinc finger
E-box-binding protein 1 (ZEB1) protein, CD44, and SNAIL1 genes. CBF1 depletion also correlated with
the inhibition of invasion in GBM cells [114], which could be due, at least in part, to the down-regulation
of the EMT inducing proteins and genes observed in these cells. To characterize the clinical importance
of CBF1, the authors assessed its predictive value by analyzing clinical data sets. This analysis showed
that CBF1 gene expression (assessed by RNA seq) was principally high in pseudopalisades and the
peri-necrotic regions of GBM, which are known to be hypoxic areas of the tumor that contain highly
invasive cells [114]. Examination of the expression levels of CBF1 in various brain tumor types
(as classified by the WHO), showed that GBM has relatively low CBF1 expression [114]. The authors
also reported that in two independent data sets (French and TCGA) there was a significant correlation
between high CBF1 and patient overall survival; however, this was not observed in another two cohorts
(German Glioma Network and Chinese cohort). CBF1 levels were significantly increased in proneural
glioblastoma as compared with any other molecular sub-groups as classified by Verhaak et al. [114,115].
Importantly, GBM with mutant IDH1 showed significantly increased CBF1 expression compared to
tumors with wild-type IDH1 [114]. In another study, in silico analysis of the TCGA data set showed
that CBF1 was highly expressed in GBM compared to non-neoplastic brain tissue [115]. This study
also showed that high expression of CBF1 in IDH wild-type GBM correlated with a slightly worse
patient’s prognosis [115]. Taking into account these two studies, it is currently still unclear if CBF1
could be a prognostic factor for GBM.
Zinc finger E-box binding Homebox 1 (ZEB1) is a transcriptional repressor which has been
shown to promote tumor invasion and metastasis [116]. Analysis of the TCGA database showed
that ZEB1 is a short survival indicator in GBM patients and a potential therapeutic target [117].
Immunofluorescence and immunohistochemistry studies using human clinical samples showed that
ZEB1 is expressed along the tumor invasive front, in pseudopalisades, which are associated with
hypoxic areas of the GBM [117,118]. In vitro studies, using a combination of inhibitory drugs and
shRNA approaches, showed that hypoxia induces ZEB1 expression and nuclear localization in GBM
cells in a HIF-1α dependent manner leading to EMT and increased migration/invasion [118,119].
ZEB1 inhibits the expression of the miRNA-200 family, which suppresses stem cell factors [116].
In GBM, the ZEB1-miRNA-200 feedback loop targets specific stem cell regulators, namely SOX2,
OLIG2, and CD133, leading to the activation of the EMT program (Figure 3). Knockdown of ZEB1
in three cell lines generated from primary glioblastoma specimens (hGBM L0, L1, and L2) inhibited
invasion [117]. Mechanistically, ZEB1 positively regulated the ROBO1 protein that has been shown
to sever the anchorage of N-cadherin to the cytoskeleton leading to increased GBM cell motility
and invasion (Figure 3) [117,120]. ZEB1 was also found to play an important role in temozolomide
resistance in GBM cells, via up-regulation of c-MYB by the ZEB1-miR-200 feedback loop. c-MYB, in
its turn, binds to the MGMT promoter in GBM cells, leading to increased expression of the MGMT
protein that repairs DNA damage caused by alkylating agents such as temozolomide (Figure 3) [117].
TWIST1 transcription factor is also a critical hypoxia induced invasion protein [121].
Physiologically, TWIST1 constitutes a master regulator of embryogenic processes, such as gastrulation
and mesoderm differentiation, via the induction of EMT [122,123]. However, TWIST1 has also been
involved in pathological processes such as tumor metastasis [121,124,125]. Analysis of TWIST1 mRNA
expression in the publically available databases, REMBRANDT and ATCG, showed that TWIST1 was
more highly expressed in GBM compared to lower grade gliomas [126]. Furthermore, within GBM,
the highest TWIST1 expression was observed in the mesenchymal subtype and lowest expression in
the proneural subtype. Elevated TWIST1 expression was also associated with poor patients’ overall
survival [126]. Immunohistochemistry analysis of TWIST1 in 269 infiltrating astrocytoma samples
showed a stronger expression of TWIST1 associated with a higher malignancy grade [126]. In addition,
positive TWIST1 expression predicted a worse patients’ outcome, which was particularly striking in
GBM patients [126]. In vitro studies showed that TWIST1 mRNA transcription is regulated by tumor
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hypoxia in a HIF-1α dependent way [127]. The TWIST1 protein was shown to promote an invasive
phenotype in GBM cells [128,129], ex vivo using organotypic brain slice cultures and in vivo using a
orthotopic xenotransplant mouse model [128]. Nevertheless, TWIST1 did not stimulate the canonical
switch between E-cadherin and N-cadherin in GBM cells [128]. Instead, TWIST1 induced changes in
cellular interactions (cell-cell and cell-substrate) and cytoskeleton reorganization through alternative
pathways in GBM to induce migration and invasion [128], described in detail in Table 1.
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Figure 3. lioblasto a ZEB1- iR -200 feedback loop interactions. In B , the ZEB1- iR -200
feedback loop targets specific stem cell regulators, namely SOX2, OLIG2, and CD133. ZEB1 up-regulation
of c-MYB by the ZEB1-miRNA-200 feedback loop leads to increased expression of the MGMT protein
that repairs DNA damage caused by alkylating agents such as temozolomide. ZEB1 positively regulates
the ROBO1 protein that has been shown to sever the anchorage of N-cadherin to the cytoskeleton
leading to increased GBM cell motility.
Table 1. T IST1 induced path ays and proteins in B .
Protein/Pathway Role
Periostin Recruitment of M2 tumor-associated macrophages which are tumor-supportive andim unosuppressive [130].
Fibronectin 1 Promotes cell cohesion and invasion of basement membrane [131].
SPARC Upholds ECM degradation through the uPA-uPAR pathway and stimulates survival, proliferation andinvasion via the PI3K pathway [132].
S AI2 Inhibits miR-34 activity, a regulatory microRNA for differentiation, promoting stemness [133,134].
ID1 Activates tumor progression pathways, such as Snail, ERK1/2 and AKT, and promotes stem cellself-renewal transcription factors Sox2, Oct3/4 and Nanog [135].
HGF Promotes survival, proliferation, transformation and invasion through activation of the PI3K/AKT,STAT3/JNK, SOS/RAS/ERK/MAPK pathways [136].
LOX Activates HIF-1α (via AKT pathway in a positive feed-back loop), FAK and VEGF gene expression [137].
Cadherin 11 Regulates cell-cell interactions and survival, and promotes cell migration [138].
BMI1/EZH2 Part of the Polycomb repressive complex 1 and 2, in that order, promotes gene silencing of the P16 andP14 tumor suppressors, and inhibits cancer stem cells differentiation [139].
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4.3. Chemokine Receptors
Several studies have shown that C-X-C chemokine receptor type 4 (CXCR4) is highly expressed
in GBM, particularly in hypoxic pseudopalisading areas, and plays a critical role in GBM cell
invasion [140–143]. Importantly, no CXCR4 staining was observed in healthy brain tissue [140,141].
These results suggest that CXCR4 expression in GBM might be modulated by hypoxia. In fact,
an in vitro study showed that hypoxia leads to the up-regulation of CXCR4 in GBM cell lines
(e.g., U87MG and LN308) in a HIF-1α dependent manner [140]. Migration of both U87MG and LN308
cells under hypoxic conditions was significantly increased compared to control normoxic cells and
the inhibition of CXCR4 significantly repressed the hypoxia-stimulated migration of GBM cells [140].
CXCR4 is a chemokine receptor for stromal cell-derived factor-1α (SDF-1α), also known as CXCL12.
HIF-1 induces SDF-1α expression on hypoxic endothelial cells [144]. Therefore, over-expression of
CXCR4 in cancer cells could lead to their migration towards blood vessels.
Inhibiting the CXCR4/SDF-1α axis following local tumor irradiation has shown significant clinical
promise and can complement standard GBM treatment. AMD3100 (Plerixafor), an inhibitor of the
CXCR4/SDF-1α interaction [145], has been shown to significantly interfere with the vasculogenesis
pathway. Treatment of GBM-bearing mice with AMD3100 immediately after irradiation prevented
the radiation-induced recruitment of bone marrow–derived cells into the tumor site and critically,
AMD3100 exposed tumors could be treated using radio-therapy regimens which were otherwise
ineffective [146]. More recently, peptide R, a new specific CXCR4 antagonist, has been developed using
a ligand-based screening approach and was shown to impair the metabolic activity and proliferation
of U87MG GBM cells. Furthermore, this agent stably reduced CXCR4 expression and cell migration in
response to CXCL12 in vitro. Peptide R was shown to reduce tumor cellularity, promote anti-tumor
features of glioma-associated microglia/macrophages and astrogliosis, and hinder intra-tumoral
vasculature [147]. Overall, CXCR4 targeted therapy has the potential to improve GBM prognosis by
supporting conventional therapeutic treatments, as well as potentially treat GBM where standard
frontline treatments fail.
C-C chemokine receptor type 5 (CCR5) mRNA levels have been shown to be significantly and
gradually up-regulated with tumor grade, grade II (N = 15), grade III (N = 15), and grade IV (N = 70)
gliomas compared to adjacent non-neoplastic brain tissues [148]. Moreover, immunohistochemistry
staining revealed that CCR5 protein expression was gradually stronger with increasing tumor
grade [148]. Kaplan–Meier analysis further showed that patients with high levels of CCR5 expression
have significantly shorter disease free survival and overall survival, indicating that CCR5 may be
a potential prognostic marker for GBM [148]. A recent study showed that hypoxia induces CCR5
up-regulation in the GBM cell line, U87MG [149]. Interestingly, hypoxia also enhanced the expression
of the CCR5 ligand, CCL4, in THP-1-derived macrophages. Knocking down CCR5 by shRNA in
U87MG cells led to a significant decrease in the invasive capability of hypoxic U87MG cells which
was concomitant with the decreased transcription of MMP-9 [149]. Even though these results are
interesting and seem to suggest a potentially important role for the CCL4-CCR5 axis in GBM invasion,
reproducibility of these experiments using other GBM model cell lines is paramount to strengthening
the significance and broadness of these findings.
Interestingly, both CXCR4 and CCR5 chemokine receptors (that have been shown to be
up-regulated by hypoxia in GBM), are co-receptors for Human Immunodeficiency Virus 1 (HIV-1).
Namely, CXCR4 is the co-receptor for strains that infect T-cells (T-tropic or X4 strains), while CCR5
is the co-receptor for HIV-1 strains that infect macrophages (M-tropic or R5 strains). For this reason,
pharmacological drugs targeting these proteins have been developed for the treatment of HIV
patients. This is in fact the case for AMD3100 [150] that has been repurposed for cancer therapy
as described above.
Studies have also been made to evaluate the use of the FDA approved HIV-1 drug, maraviroc
(Pfizer) [151], for the treatment of GBM. Maraviroc is a CCR5 receptor antagonist [152]. Treatment of
cancer patients with maraviroc has shown promising results in inhibiting invasion and metastasis in
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different types of cancer [153–156]. Unfortunately, to date, the results regarding the use of this drug for
GBM treatment are disappointing. A study tested several currently marketed non-chemotherapeutic
agents for their ability to enhance/synergize the effect of temozolomide, the current standard
chemotherapeutic drug used in the clinic for GBM treatment [157]. This study found that maraviroc
(20–180 µM) had no cytotoxic effect against the GBM cell line, GAMG.
4.4. Cytoskeleton Dynamics
Microarray-based gene expression studies using glioma or neuroblastoma cells have shown
that knockdown of HIF-1α inhibits the expression of the cyclin G2 encoding gene, ccng2 [76,158,159].
Furthermore, immunohistochemistry studies showed the expression of cyclin G2 in hypoxic regions
of GBM, principally in pseudopalisades [160]. In addition, in vitro studies using U87MG, U251MG,
and LNZ308 GBM cell lines showed a significant up-regulation of cyclin G2 expression in response to
hypoxia [160]. This study also showed that HIF-1α binds to the ccng2 promoter and that knockdown
of HIF-1α by shRNA inhibited the hypoxia-induced expression of cyclin G2. These results indicate that
hypoxia is a main regulator of cyclin G2 expression in GBM. Cyclin G2 was first identified as a negative
regulator of the cell cycle [161] and later it was shown to induce cell cycle arrest in a p53-dependent
manner [162]. Moreover, cyclin G2 was also shown to bind to and stabilize microtubules [162]. A more
recent study demonstrated that cyclin G2 plays an important role in the regulation of hypoxia induced
migration and invasion in GBM cells (e.g., U87MG and U251MG) [160]. This study revealed that
mechanistically cyclin G2 is able to recruit cortactin to the leading edge of migrating GBM cells,
promoting the subsequent tyrosine phosphorylation of cortactin, which is essential for ruffle formation
and tumor cell invasion [160].
4.5. Hemostasis
Tissue factor (TF) has been shown to be upregulated in GBM cells in response to hypoxia [25,163,164].
TF is a main regulator of hemostasis, initiating the blood coagulation cascade upon binding to its ligand,
factor VII (FVII) [165]. Expression of TF has been shown to positively correlate with the histological
grade of gliomas, as well as with the extent of necrosis [166]. A more recent analysis of a large patient
cohort of the TCGA data platform (N = 424) revealed that TF mRNA levels are significantly upregulated
in GBM compared to normal brain tissue samples [167]. Kaplan–Meier survival analysis of the
REMBRANDT database (N = 213) further determined a significant reduction in overall survival in GBM
patients with high levels of TF expression [167]. Moreover, immunohistochemistry studies revealed that
TF is predominantly expressed in perinecrotic and perivascular areas of human GBM [167]. Given the
key role of TF in the regulation of blood clotting, increased expression of this protein in tumor
cells has been shown to correlate with hyper-coagulation in malignant gliomas, further promoting
a hypoxic environment [25,165]. In addition to its pro-thrombotic function, TF has also been shown
to constitute a transmembrane receptor that regulates intracellular signaling pathways [165,168,169].
TF/Factor VII (FVII) signaling has been shown to play an important role in glioma cell growth,
migration, and invasion [170]. This study suggested that the effects of TF/FVII were mediated through
the downstream activation of PAR-2 and the ERK1/2 MAPK signaling pathways.
There has been some limited research focusing on targeting TF directly (as opposed to ERK 1/2
MAPK inhibitors). A murine xenograft model where human GBM cells of MZ-18 were transplanted
into nude mice brains showed that treatment of these mice with a monoclonal antibody against TF
(mAb TF9-10H10), using an intracranial osmotic pump system for delivery, significantly inhibited
MZ-18 cell invasion compared to mock-treated control animals [167]. The extent of activated blood
vessels was also reduced upon anti-TF treatment. These results suggest that targeting TF might
be a promising treatment strategy for GBM therapy, by inhibiting both tumor invasion and tumor
vasculature. However, clinical trials still need to be performed to test these encouraging results in
GBM patients.
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4.6. Others
Over-expression of the pro-motility receptor protein tyrosine kinase, ephrin type-A receptor 2 (EphA2),
has been observed in GBM and associated with poor prognosis/lower overall survival [171–173].
In vitro studies have further shown that EphA2 induces GBM cell motility and invasion [174–176].
EphA2 activity is antagonized by the EphA2 ligand, ephrin A1 [151,154,155], which is frequently
suppressed in GBM, further promoting EphA2 signaling [172,177]. EphA2 coordinates signaling from
a variety of receptor tyrosine kinases (RTKs) via growth factor mediated activation of AKT, which
initiates AKT-dependent EphA2 phosphorylation at residue S897 [175]. The resulting P-S897-EphA2
is required for lamellipodia formation and subsequent GBM cell motility and invasion [175].
The eHsp90/LRP1 complex was identified as a key regulator of EphA2-dependent GBM cell motility
and invasion through its ability to sustain AKT-dependent phosphorylation of EphA2 at residue
S897 [178]. Interestingly, hypoxia elicited increased expression and cell surface levels of both eHsp90
and LRP1 in G48a, U87MG, and U251 GBM cells. Moreover, hypoxia-mediated up-regulation of
eHsp90 and LRP1 led to amplification of the eHsp90-LRP1 signaling axis, as assessed by robust
activation of AKT and EphA2, and concomitantly induced cell motility and invasion [178].
Efforts have been made in the development of HSP90-directed therapies. Several pharmacological
inhibitors that target the N-terminal ATP-binding domain of HSP90 have been developed, including
ansamycins, purine analogs, and resorcinol derivatives [179,180]. Preclinical and clinical trials have
demonstrated the antitumor efficacy of these drugs in different cancer types [180,181]. However, to
date, no clinical trials with HSP90 inhibitors have been performed in GBM patients.
Transient receptor potential 6 (TRPC6) mRNA and protein levels have been shown to be
up-regulated in GBM samples compared to normal brain tissue [182,183]. TRPC6 is a member
of the Transient Receptor Potential (TRP) superfamily of cation channels [184]. In vitro studies
using a combination of inhibitory drugs and shRNAs for Notch1 or TRPC6, showed that hypoxia
induces the expression of TRPC6 in a Notch1 dependent manner in U373MG GBM cells [182].
Mechanistically, hypoxia induced TRPC6 expression caused a sustained elevation of intracellular
calcium levels leading to the activation of the calcineurin-nuclear factor of the activated T-cell (NFAT)
signaling pathway and subsequent promotion of GBM cell growth, invasion, and angiogenesis [182].
5. Conclusions
GBM, the most common and deadly type of brain tumor, is characterized by extensive hypoxic
foci that trigger an invasive cancer cell phenotype. Tumor invasion is a major contributor to GBM
chemoresistance and patients’ mortality. For this reason, the identification and characterization of
proteins involved in hypoxia induced invasion in GBM is critical for the development of novel and
more effective therapies against this deadly disease. The treatment protocol for GBM patients has
not changed since 2005, and temozolomide treatment in particular has been shown to be primarily
limited to tumors with MGMT promoter methylation [5]. In this review, we have compiled, to
the best of our knowledge, the progress made in identifying hypoxia responsive invasive proteins
in GBM, the molecular mechanisms by which these proteins contribute to GBM migration and
invasion, and the advancements made regarding the development of pharmacological drugs against
these proteins. Proteins involved in ECM degradation and remodeling (e.g., CAIX, integrins β3,
αvβ3 and αvβ5, PLOD2, MMP-2, MMP-9); EMT (e.g., CBF1, ZEB1, TWIST1); chemokine receptors
(e.g., CXCR4, CCR5); cytoskeleton dynamics (e.g., cyclin G2); hemostasis (e.g., TF, factor VII); the
pro-motility receptor, EphA2; and the cation channel protein, TRPC6, have been shown to contribute
to GBM migration and invasion in response to hypoxia. Of these, CAIX, integrins, PLOD2, CXCR4,
EGFRvIII (that induces up-regulation of MMP-2, MMP-9, and integrin β3 in a HIF-1α/hypoxia
dependent manner), HSP90 (which induces hypoxic activation of EphA2) and to a limited extent TF
have been shown to be potentially promising targets for GBM treatment. Phase I and II trials are
currently being pursued for CAIX, EGFRvIII, PLOD2, and EphA2 targeting chemotherapeutics in
different types of cancer. However, clinical trials in GBM patients have not yet been reported for these
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drugs. Even though a phase III study for the integrins targeting drug, cilengitide (CENTRIC), in newly
diagnosed GBM patients showed disappointing results, another independent phase II study with
this drug (CORE) showed that bi-weekly treatment with cilengitide alongside conventional therapy
significantly improved overall patient survival. While the CENTRIC study was performed in patients
with GBM tumors containing a methylated MGMT promoter, the CORE study was done in patients
with an un-methylated MGMT promoter. These results suggest that cilengitide might be beneficial in
the treatment of tumors with an un-methylated MGMT promoter.
A major obstacle for brain tumor treatment is the BBB. Many of the chemotherapeutics that have
shown promising in vitro results against GBM cells do not have the capacity to cross the BBB. For this
reason, the development of drug delivery systems that can transport these drugs through the BBB is
equally imperative.
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